Related Experiment Videos

The effect of combination therapy on regression of left ventricular hypertrophy in cases with hypertension

Bahar Boydak1, Sanem Nalbantgil, Hasan Yilmaz

  • 1Department of Emergency Cardiology, Faculty of Medicine, Ege University, 1780/2 sokak, No. 9 D. 1, 35530 Karsiyaka, Izmir, Turkey. boydak@med.ege.edu.tr

Saudi Medical Journal
|February 16, 2005
PubMed

Insights

Angiotensin-converting enzyme inhibitor (ACE-I) plus calcium channel blocker combination therapy shows superior regression of left ventricular hypertrophy (LVH) compared to ACE-I plus diuretic in hypertensive patients. Both combinations effectively lower blood pressure.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Antihypertensive drugs exhibit varying effects on left ventricular hypertrophy (LVH) regression.
  • Limited comparative data exist on combination therapies for LVH regression in hypertension.

Purpose of the Study:

  • To compare the efficacy of two antihypertensive combination therapies in regressing left ventricular hypertrophy (LVH).
  • To evaluate ACE-I plus calcium channel blocker versus ACE-I plus diuretic in patients with uncontrolled hypertension on ACE-I monotherapy.

Main Methods:

  • A 6-month randomized study involving 40 hypertensive patients.
  • Group 1: Lisinopril (ACE-I) + Nifedipine (calcium channel blocker).
  • Group 2: Lisinopril (ACE-I) + Hydrochlorothiazide (diuretic).
  • Blood pressure, echocardiography, and laboratory analyses were performed pre- and post-treatment.

Main Results:

  • Both combination therapies significantly reduced systolic and diastolic blood pressure.
  • Left ventricular mass index (LVMI) decreased significantly in both groups.
  • A greater reduction in LVMI was observed in the ACE-I plus calcium channel blocker group.

Conclusions:

  • ACE-I plus calcium channel blocker and ACE-I plus diuretic combinations offer similar blood pressure control.
  • ACE-I plus calcium channel blocker combination therapy demonstrates superior efficacy in regressing LVH compared to ACE-I plus diuretic.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...